Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline + Esreboxetine Combination vs Monotherapies in MDD
NCT00636246Phase 2Completed
- Sponsor
- Viatris
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of esreboxetine in major depressive disorder (MDD) (8 arms), sponsored by Viatris. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Jun 2004; status: completed.
02
Drugs
esreboxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00636246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00636246.